I

Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovenský, Jozef, Payer, Juraj, Herold, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123502/
http://dx.doi.org/10.1007/978-3-319-21335-4_9
_version_ 1783515651016491008
author Rovenský, Jozef
Payer, Juraj
Herold, Manfred
author_facet Rovenský, Jozef
Payer, Juraj
Herold, Manfred
author_sort Rovenský, Jozef
collection PubMed
description Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral dose of 150 mg is given once a month, a regimen thought to improve compliance. It can also be administered by slow intravenous injection at a dose of 3 mg in 3ml every 3 months. This is particularly useful in patients with gastrointestinal intolerance of bisphosphonates.
format Online
Article
Text
id pubmed-7123502
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-71235022020-04-06 I Rovenský, Jozef Payer, Juraj Herold, Manfred Dictionary of Rheumatology Article Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral dose of 150 mg is given once a month, a regimen thought to improve compliance. It can also be administered by slow intravenous injection at a dose of 3 mg in 3ml every 3 months. This is particularly useful in patients with gastrointestinal intolerance of bisphosphonates. 2015-07-02 /pmc/articles/PMC7123502/ http://dx.doi.org/10.1007/978-3-319-21335-4_9 Text en © Springer International Publishing Switzerland 2016 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Rovenský, Jozef
Payer, Juraj
Herold, Manfred
I
title I
title_full I
title_fullStr I
title_full_unstemmed I
title_short I
title_sort i
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123502/
http://dx.doi.org/10.1007/978-3-319-21335-4_9
work_keys_str_mv AT rovenskyjozef i
AT payerjuraj i
AT heroldmanfred i

Ejemplares similares